甘李药业：博凡格鲁肽注射液Ⅱ期临床试验完成首例受试者给药

Core Viewpoint - Ganli Pharmaceutical (603087) has announced that its self-developed injection, Bofang Glutide, is currently undergoing Phase II clinical trials in the United States, with the first subject successfully dosed recently [1] Group 1: Product Development - Bofang Glutide is a GLP-1 receptor agonist (GLP-1RA) designed for bi-weekly administration [1] - The product aims to treat adult patients with type 2 diabetes and assist in weight management for overweight or obese individuals [1]